GGrantIndex
← Leaderboards

Joseph Anthoney Vetro

University Of Nebraska Medical Center

$4,871,710
Attributed
$4,871,710
Total exposure
7
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $996.7K · FY200720
$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20

Funding mix

By agency

NIH$4,871,710 · 7

By mechanism

R01$3,476,160 · 2
P20$669,990 · 3
R21$400,575 · 1
R41$324,985 · 1

Top collaborators

No co-investigators on record.

Most similar at University Of Nebraska Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Mouse Model

Research focus

Mouse ModelModificationProteinsUnited States National Institutes Of HealthSurfaceAttenuatedLeadPublic HealthMissionIn VitroClinical TrialsAgonistC5a Anaphylatoxin ReceptorPathogenAntigen-Presenting CellsInfectionCell SurfaceCellsStructureTumorCaliberDoseNanoparticleCancer Therapy

Grant awards (15)

Host-Directed Immunotherapy: A "One Health" Approach$620,473
R01 · FY2020 · AI · contact PI
EP67-Based Targeted Mucosal Vaccines to Prevent Primary Infection with CMV$376,250
R01 · FY2020 · AI · contact PI
EP67-Based Targeted Mucosal Vaccines to Prevent Primary Infection with CMV$376,250
R01 · FY2019 · AI · contact PI
Host-Directed Immunotherapy: A "One Health" Approach$342,748
R01 · FY2019 · AI · contact PI
EP67-Based Targeted Mucosal Vaccines to Prevent Primary Infection with CMV$376,250
R01 · FY2018 · AI · contact PI
Host-Directed Immunotherapy: A "One Health" Approach$355,373
R01 · FY2018 · AI · contact PI
EP67-Based Targeted Mucosal Vaccines to Prevent Primary Infection with CMV$376,192
R01 · FY2017 · AI · contact PI
Host-Directed Immunotherapy: A "One Health" Approach$263,848
R01 · FY2017 · AI · contact PI
EP67-Based Targeted Mucosal Vaccines to Prevent Primary Infection with CMV$388,776
R01 · FY2016 · AI · contact PI
Development of Chol-DsiRNA Polyplexes to Improve the Therapy of Breast Cancer$324,985
R41 · FY2016 · TR · contact PI
TARGETED NANOCARRIER FOR SIRNA DELIVERY TO TUMOR VASCULATURE$223,081
P20 · FY2011 · RR · contact PI
TARGETED NANOCARRIER FOR SIRNA DELIVERY TO TUMOR VASCULATURE$225,335
P20 · FY2010 · RR · contact PI
TARGETED NANOCARRIER FOR SIRNA DELIVERY TO TUMOR VASCULATURE$221,574
P20 · FY2009 · RR · contact PI
Development of Targeted Nanogels for siRNA Delivery to Tumor Vasculature$180,075
R21 · FY2008 · EB · contact PI
Development of Targeted Nanogels for siRNA Delivery to Tumor Vasculature$220,500
R21 · FY2007 · EB · contact PI